Cantor Fitzgerald initiated coverage of Agios Pharmaceuticals with an Overweight rating and no price target. Cantor views Agios’s Pyrukynd as an overlooked asset for two large, underserved hematology indications, thalassemia and sickle cell disorder, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AGIO:
- Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024
- Agios Pharmaceuticals price target raised to $31 from $30 at JPMorgan
- Agios Pharmaceuticals announces anticipated 2024 milestones
- Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
- Biotech Alert: Searches spiking for these stocks today